Nektar Therapeutics (NKTR.OQ)
4 Dec 2013
|Market Cap (Mil.):||$1,352.74|
|Shares Outstanding (Mil.):||116.12|
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49sfor the Morning News Call newsletter http://link.reuters.com/nex49s) U.S. stocks fell at the open on Friday, with the S&P 500 and Dow poised to drop for the first week in four, as concerns grew over a lack of compromise in debt and budget negotiations by congressional lawmakers in Washington. The Dow Jones industrial average was down 0.27 percent, the S&P 500 was down 0.
- Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.
|Takeda Pharmaceutical Company Limited (4502.T)||¥4,995||-45.00|
|Eisai Co., Ltd (4523.T)||¥3,965||0.00|
|NOF CORPORATION (4403.T)||¥698||0.00|
|Dr. Reddy's Laboratories Limited (REDY.NS)||Rs2,414.75||-35.10|
|Novo Nordisk A/S (NOVOb.CO)||kr.981.50||+7.00|
|Pfizer Inc. (PFE.N)||$31.17||-0.05|
|Novartis AG (NOVN.VX)||CHF70.70||+0.05|
|Roche Holding Ltd. (ROG.VX)||CHF244.80||+0.20|
|GlaxoSmithKline plc (GSK.L)||1,600.85p||+8.00|
|Eli Lilly & Co. (LLY.N)||$49.86||+0.08|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Ford Investor Services, Inc.
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NEKTAR THERAPEUTICS including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.